Diseases / Cholangiocarcinoma
Cholangiocarcinoma
DiseaseCholangiocarcinoma is bile duct cancer, an adenocarcinoma arising from the biliary epithelium that can occur intrahepatically or extrahepatically. It is often diagnosed at advanced stages and generally has poor prognosis.
- Trials
- 770
- Recruiting
- 155
- Completed
- 223
- With results
- 96
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | — | — | 1 | 1 | — | 2 | — | — | — | — | — | 6 |
| Phase 1 | 18 | 3 | — | 12 | 36 | 23 | 5 | 1 | 9 | — | — | — | 107 |
| Phase 1/2 | 10 | 2 | 1 | 5 | 17 | 12 | — | — | 7 | — | — | — | 54 |
| Phase 2 | 50 | 18 | 2 | 23 | 86 | 30 | 12 | 1 | 37 | — | — | — | 259 |
| Phase 2/3 | 4 | 2 | — | 4 | — | 2 | — | — | 5 | — | — | — | 17 |
| Phase 3 | 5 | 3 | — | 4 | 7 | 8 | 1 | — | 10 | — | — | — | 38 |
| Phase 4 | 1 | — | — | — | 2 | — | 1 | — | 4 | — | — | — | 8 |
| Not applicable | 26 | 10 | 1 | 5 | 29 | 13 | 5 | — | 28 | — | — | — | 117 |
| Unknown | 39 | 16 | 3 | 4 | 45 | 10 | 6 | 1 | 34 | 2 | 2 | 2 | 164 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | 6 | 107 | 54 | 259 | 17 | 38 | 8 | 117 | 164 | 770 |
| Pancreatic Neoplasms | 1 | 31 | 8 | 15 | — | 1 | 2 | 24 | 41 | 123 |
| Carcinoma, Hepatocellular | — | 18 | 5 | 21 | — | 2 | 2 | 23 | 43 | 114 |
| Gallbladder Neoplasms | — | 14 | 8 | 48 | 2 | 11 | 1 | 7 | 18 | 109 |
| Biliary Tract Neoplasms | — | 11 | 10 | 40 | 4 | 8 | — | 6 | 18 | 97 |
| Colorectal Neoplasms | — | 34 | 9 | 17 | — | 1 | 1 | 9 | 15 | 86 |
| Liver Neoplasms | — | 13 | 5 | 12 | 1 | 1 | — | 10 | 32 | 74 |
| Stomach Neoplasms | 1 | 29 | 11 | 10 | — | 1 | — | 5 | 16 | 73 |
| Bile Duct Neoplasms | — | 9 | 6 | 26 | 2 | 6 | — | 6 | 16 | 71 |
| Ovarian Neoplasms | 1 | 23 | 7 | 8 | 1 | — | — | 2 | 9 | 51 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 22 | 0 |
| 2 | Shanghai Zhongshan Hospital | 16 | 2 |
| 3 | Mayo Clinic | 14 | 0 |
| 4 | Fudan University | 12 | 1 |
| 5 | Tianjin Medical University Cancer Institute and Hospital | 11 | 1 |
| 6 | M.D. Anderson Cancer Center | 10 | 0 |
| 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 9 | 0 |
| 8 | Peking Union Medical College Hospital | 8 | 0 |
| 9 | Sun Yat-sen University | 8 | 0 |
| 10 | Washington University School of Medicine | 8 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Gemcitabine | 118 |
| 2 | Cisplatin | 82 |
| 3 | Oxaliplatin | 46 |
| 4 | pembrolizumab | 37 |
| 5 | Capecitabine | 33 |
| 6 | Fluorouracil | 33 |
| 7 | durvalumab | 30 |
| 8 | lenvatinib | 28 |
| 9 | Leucovorin | 27 |
| 10 | Magnetic Resonance Spectroscopy | 18 |
Evidence
- Results reported
- 43%96 of 223 completed
- Published
- 16.1%36 of 223 completed
- Primary endpoint met
- 46.7%7 of 15 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 57
- Median duration
- 40.7months
- Countries
- 58
- Study sites
- 5502
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 10
- Phase 1
- 38
- Phase 1/2
- 72
- Phase 2
- 40
- Phase 2/3
- 150
- Phase 3
- 188
- Phase 4
- 47
- Not applicable
- 60
- Unknown
- 168
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 98 |
| 2 | New York | United States | 88 |
| 3 | Shanghai | China | 63 |
| 4 | Seoul | South Korea | 60 |
| 5 | Boston | United States | 59 |
| 6 | Los Angeles | United States | 53 |
| 7 | Chicago | United States | 52 |
| 8 | Rochester | United States | 49 |
| 9 | Dallas | United States | 48 |
| 10 | Nashville | United States | 47 |
Terminations
- Terminated
- 98
- Withdrawn
- 32
- Suspended
- 3
- Stopped for recruitment
- 4.4%34 of 770 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04985357 Withdrawn | Withdrawn | Abandoned prior to launch. | 2030-05-31 |
| NCT05514912 Withdrawn | Withdrawn | PI has decided to terminate this study due to study supporter pulling support on this study. | 2027-06-23 |
| NCT06572189 Withdrawn | Withdrawn | Based on the results of another intravenous injection therapy CD-801 for the treatment of hepatocellular carcinoma, we have decided to change the administration method and therefore withdraw this trial protocol. | 2026-07-31 |
| NCT02626312 Terminated | Terminated | \< 75% participation | 2026-06-10 |
| NCT05712356 Terminated | Terminated | The study was halted prematurely to allow analysis of the results. | 2026-04-05 |
| NCT05325866 Terminated | Terminated | Sponsor Decision | 2026-01-28 |
| NCT05346484 Terminated | Terminated | Portfolio prioritization | 2026-01-12 |
| NCT02917759 Terminated | Terminated | Lack of funding to support enrollment | 2025-12-31 |
| NCT06284226 Withdrawn | Withdrawn | The project is terminated | 2025-12-31 |
| NCT05275478 Terminated | Terminated | Sponsor Decision - Business Decisions | 2025-12-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Cholangiocarcinoma trials on ClinicalTrials.gov →